• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Investigators hit pause on trials following concerns over paclitaxel-coated devices

December 18, 2018 By Sarah Faulkner

American Heart AssociationA meta-analysis published in the Journal of the American Heart Association last week suggested that patients treated with paclitaxel-coated balloons and stents for peripheral artery disease could be at a higher risk for late death compared to people treated with uncoated balloons.

The results of the study prompted investigators for two trials to stop their studies. Meanwhile, leaders in the endovascular community have promised to hold a special forum to discuss the study’s findings.

Led by Dr. Konstantinos Katsanos, researchers looked at data from 28 trials and discovered that there was a 68% relative risk increase in all-cause death with paclitaxel-coated devices after two years and a 93% relative risk increase after five years compared to therapy with an uncoated balloon.

The lead researcher told TCTMD that he was happy with the community’s response to his study.

“The role of regulatory agencies like the FDA is also very important here, and I know that a lot of people – including myself – are eagerly waiting for clarifications and a more in-depth assessment of the different devices,” he said.

In a notice to study centers, investigators for the Basil-3 trial wrote that recruitment for the study will be paused until January while a committee reviews the trial data.

“Whilst the population of the reviewed trials differs from those in the BASIL-3 trial, it is clearly important new information that may cause concerns for the BASIL-3 trial in relation to patient safety. As such, it raises the need to consider whether changes to the trial protocol and patient information are required. We have therefore decided to suspend recruitment to the trial, pending further discussions,” the researchers wrote.

Investigators for the Swedepad trial also stopped recruitment for its studies, citing Katsanos’ analysis.

Katsanos, however, told TCTMD that he is unsure why the investigators decided to hit pause on their trials.

“As long as there are no safety concerns from the study monitors, I personally believe that all clinical studies need to continue, as they may provide invaluable evidence to decide on the safety and effectiveness of paclitaxel treatments in general,” he told the news outlet. “In addition, it is imperative that already completed studies start collecting longer-term follow-up data of at least 2 years.”

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals, Vascular

IN CASE YOU MISSED IT

  • TerSera touts study results of infusion reaction prevention treatment
  • Cannabinoid treatment developer SciSparc raises $8.15M
  • Senseonics sinks on mixed bag Q4, massive bottom-line slide
  • Pulmatrix completes $40M offering, updates product pipeline timetable
  • Amgen to acquire Five Prime Therapeutics for $1.9B

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS